Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR). To contextualize eff...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shaji Kumar, Sundar Jagannath, Katja C. Weisel, Laura Rosiñol, Xavier Leleu, Meletios-Athanasios Dimopoulos, Efstathios Kastritis, David S. Siegel, Jorge Monge, Juan Du, Javier de la Rubia, Pedro Asensi Cantó, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Blade, Shuji Ozaki, Meral Beksac, Fernando Escalante, Madhu Nagaraj, Rafla Hassan, Nicolle Bonar, Paul Spin, Mostafa Shokoohi, Muhaimen Siddiqui, Di Wang, Kevin Hou, Michael E. D. West, Christian Hampp, Jeannette Green, Olivier Humblet, Alexander Breskin, James Harnett, Wenzhen Ge, Rachel E. Sobel, Jessica J. Jalbert, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Brian G. M. Durie
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Publishing Group 2026-03-01
Col·lecció:	Blood Cancer Journal
Accés en línia:	https://doi.org/10.1038/s41408-026-01466-2
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!